Medico Remedies Ltd. (MEDICO) AI Stock Analysis

• Market Cap: ₹3.41B
• Dividend Yield: N/A
• Average Volume (3M): 23.63K
• Price to Earnings (P/E): 33.8
• Beta (1Y): 0.25
• Revenue Growth: 4.15%
• EPS Growth: 21.74%
• Country: IN
• Employees: 193
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 82,984,000
• 10 Day Avg. Volume: 20,899
• 30 Day Avg. Volume: 23,628
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹45.00
• Price Target Upside: 14.42% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 61 Neutral
• Price Target: ₹45.00 ▲(14.42% Upside)

Medico Remedies Ltd. has strong financial fundamentals and growth potential, but faces bearish technical indicators and high valuation multiples. Investors should consider the balance of growth prospects against current valuation and market momentum.

Medico Remedies Ltd. Business Overview & Revenue Model

Company Description

Medico Remedies Ltd. (MEDICO) is a pharmaceutical company engaged in the manufacturing and marketing of a wide range of pharmaceutical formulations. The company operates in the healthcare sector, providing essential medications in various therapeutic segments such as antibiotics, anti-inflammatories, and cardiovascular drugs. Medico Remedies focuses on delivering high-quality and affordable pharmaceutical products to both domestic and international markets.

How the Company Makes Money

Medico Remedies Ltd. generates revenue primarily through the sale of its pharmaceutical products. The company's revenue model is based on the manufacturing and distribution of generic and branded formulations across different therapeutic categories. Medico Remedies earns income by supplying its products to hospitals, pharmacies, and healthcare providers. Additionally, the company has established partnerships with distributors and agents to enhance its market reach. Export sales contribute significantly to its earnings, as Medico Remedies exports its products to various international markets, benefiting from global demand for cost-effective healthcare solutions.

Medico Remedies Ltd. Financial Statement Overview

Summary

Medico Remedies Ltd. shows strong revenue growth and improving profitability with a solid equity position and prudent leverage management. However, volatility in EBIT margin and capital expenditure impacts on free cash flow require monitoring.

Income Statement

Medico Remedies Ltd. demonstrates strong revenue growth with a consistent increase in total revenue over the past years, indicating robust business expansion. The gross profit margin is healthy, reflecting effective cost management relative to revenue. Additionally, the net profit margin shows improvement, highlighting enhanced profitability. However, the EBIT margin appears to be less stable, suggesting potential volatility in operating efficiency, which needs attention.

Balance Sheet

The company's balance sheet shows a solid equity base with a favorable debt-to-equity ratio, indicating prudent leverage management. The return on equity is improving, showcasing effective utilization of shareholder funds. However, the equity ratio suggests a moderate reliance on liabilities, which could pose risks if not managed carefully.

Cash Flow

Medico Remedies Ltd. exhibits positive free cash flow growth, which is a positive indicator of financial health and capacity for reinvestment. The operating cash flow to net income ratio is strong, highlighting effective conversion of income into cash. However, the free cash flow to net income ratio is lower, suggesting that capital expenditures are absorbing a significant portion of free cash flow, which may impact future liquidity if not controlled.

Breakdown	Mar 2025	Mar 2023	Mar 2024	Mar 2022	Mar 2021
Income Statement
Total Revenue	1.51B	1.40B	1.45B	1.18B	1.22B
Gross Profit	426.11M	355.66M	175.25M	226.30M	234.09M
EBITDA	150.03M	135.66M	177.36M	93.34M	62.59M
Net Income	100.93M	72.42M	82.91M	48.12M	25.90M
Balance Sheet
Total Assets	1.20B	874.48M	961.95M	761.90M	756.21M
Cash, Cash Equivalents and Short-Term Investments	25.45M	21.95M	15.46M	23.40M	38.86M
Total Debt	147.00M	97.62M	80.50M	106.10M	150.53M
Total Liabilities	573.30M	436.05M	438.24M	388.70M	431.63M
Stockholders Equity	624.69M	438.43M	523.71M	373.20M	324.58M
Cash Flow
Free Cash Flow	17.07M	15.75M	2.04M	-11.50M	4.72M
Operating Cash Flow	48.92M	81.67M	26.83M	17.10M	26.08M
Investing Cash Flow	-34.60M	-66.03M	-27.70M	-28.60M	-751.83K
Financing Cash Flow	-5.20M	-18.17M	-4.90M	74.00M	-3.51M

Medico Remedies Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 39.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDICO, the sentiment is Neutral. The current price of 39.33 is below the 20-day moving average (MA) of 39.88, below the 50-day MA of 42.88, and below the 200-day MA of 53.47, indicating a neutral trend. The MACD of -0.69 indicates Negative momentum. The RSI at 50.89 is Neutral, neither overbought nor oversold. The STOCH value of 58.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:MEDICO.

Medico Remedies Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALBERTDAVD	65 Neutral	₹4.66B	74.06		0.61%	-9.14%	-91.11%
Sector *	64 Neutral	€6.01B	18.22	-2.83%	2.07%	0.38%	-36.73%
MEDICO	61 Neutral	₹3.41B	33.79		―	4.15%	21.74%
SMSLIFE	60 Neutral	₹3.27B	18.93		0.13%	3.34%	-3.39%
LYKALABS	58 Neutral	₹3.56B	47.46		―	19.40%	1286.88%
BROOKS	56 Neutral	₹4.51B	391.42		―	3.86%	50.63%
ZIMLAB	54 Neutral	₹3.68B	39.17		―	-3.36%	-47.58%